Drug intelligence / Profile preview

DH001

Development stage: Phase 2
Lead developer: Monyan Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DH001 is an orally bioavailable small molecule drug under development primarily as a cardioprotective agent. Its main investigated use is for the prevention of doxorubicin-induced cardiotoxicity in cancer patients. The drug is being developed by Monyan Pharmaceutical and has reached Phase 2 clinical trials in China for both neoplasms and drug-induced cardiotoxicity. While its precise mechanism of action has not been publicly disclosed, it is designed to reduce or prevent cardiac damage associated with certain chemotherapeutic agents[1][2][3][4].

Other names: DH001 tabletsDH-001 tabletsDH 001 tablets

Beyond the preview

Go deeper on DH001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DH001.

Explore the full profile